An Insulin-Chromogranin A Hybrid Peptide Activates DR11-Restricted T Cells in Human Type 1 Diabetes
Diabetes · 2024
DOI: 10.2337/db23-0622 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Aïsha Callebaut und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Immunology, Benaroya Research Institute, Seattle, WA. Hauptthemen laut MEDLINE: Insulin, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDDK NIH HHS, National Institute of Allergy and Infectious Diseases.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Hybrid insulin peptides (HIPs) formed through covalent cross-linking of proinsulin fragments to secretory granule peptides are detectable within murine and human islets. The 2.5HIP (C-peptide–chromogranin A [CgA] HIP), recognized by the diabetogenic BDC-2.5 clone, is a major autoantigen in the nonobese diabetic mouse. However, the relevance of this epitope in human disease is currently unclear. A recent study probed T-cell reactivity toward HIPs in patients with type 1 diabetes, documenting responses in one-third of the patients and isolating several HIP-reactive T-cell clones. In this study, we isolated a novel T-cell clone and showed that it responds vigorously to the human equivalent of the 2.5HIP (designated HIP9). Although the responding patient carried the risk-associated DRB1*04:01/DQ8 haplotype, the response was restricted by DRB1*11:03 (DR11). HLA class II tetramer staining revealed higher frequencies of HIP9-reactive T cells in individuals with diabetes than in control participants. Furthermore, in DR11+ participants carrying the DRB4 allele, HIP9-reactive T-cell frequencies were higher than observed frequencies for the immunodominant proinsulin 9-28 epitope. Finally, there was a negative correlation between HIP9-reactive T-cell frequency and age at diagnosis. These results provide direct evidence that this C-peptide–CgA HIP is relevant in human type 1 diabetes and suggest a mechanism by which nonrisk HLA haplotypes may contribute to the development of β-cell autoimmunity. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Translational Immunology, Benaroya Research Institute, Seattle, WA.
- Laboratory of Clinical and Experimental Endocrinology, Catholic University of Leuven, Leuven, Belgium.
- Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.
- Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO.
ORCID-Profile: Chantal Mathieu, Eddie A James
Förderung
- NIAID NIH HHS
- NIDDK NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive Diseases
Zitieren
APA
Callebaut, A., Guyer, P., Baker, R. L., Gallegos, J. B., Hohenstein, A. C., Gottlieb, P. A., Mathieu, C., Overbergh, L., Haskins, K., & James, E. A. (2024). An Insulin-Chromogranin A Hybrid Peptide Activates DR11-Restricted T Cells in Human Type 1 Diabetes. Diabetes. https://doi.org/10.2337/db23-0622
Vancouver
Callebaut A, Guyer P, Baker RL, Gallegos JB, Hohenstein AC, Gottlieb PA, et al. An Insulin-Chromogranin A Hybrid Peptide Activates DR11-Restricted T Cells in Human Type 1 Diabetes. Diabetes. 2024. doi:10.2337/db23-0622
BibTeX
@article{Callebaut2024,
author = {Callebaut, Aïsha and Guyer, Perrin and Baker, Rocky L and Gallegos, Joylynn B and Hohenstein, Anita C and Gottlieb, Peter A and Mathieu, Chantal and Overbergh, Lut and Haskins, Kathryn and James, Eddie A},
title = {An Insulin-Chromogranin A Hybrid Peptide Activates DR11-Restricted T Cells in Human Type 1 Diabetes},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db23-0622}
}
EUVIMED